stocks logo

TMCI

Treace Medical Concepts Inc
$
7.850
-0.470(-5.650%)
  • Overview
  • Forecast
  • Valuation
High
7.950
Open
7.830
VWAP
7.83
Vol
261.95K
Mkt Cap
520.99M
Low
7.675
Amount
2.05M
EV/EBITDA(TTM)
--
Total Shares
62.01M
EV
503.00M
EV/OCF(TTM)
--
P/S(TTM)
2.49

Treace Medical Concepts, Inc. is a medical technology company. The Company’s Lapiplasty three-dimensional (3D) Bunion Correction System is a combination of instruments, implants and surgical methods designed to surgically correct all three planes of ...Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q1
FY2025Q2
FY2025Q3
52.07M
+1.88%
--
--
49.52M
+11.39%
--
--
49.92M
+10.71%
--
--
Estimates Revision
The market is revisingUpwardthe revenue expectations for Treace Medical Concepts, Inc. (TMCI) for FY2025, with the revenue forecasts being adjusted by 0.69%over the past three months. During the same period, the stock price has changed by-0.63%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.69%
In Past 3 Month
Stock Price
Go Down
down Image
-0.63%
In Past 3 Month
6 Analyst Rating
up Image
46.50% Upside
Wall Street analysts forecast TMCI stock price to riseover the next 12 months. According to Wall Street analysts, the average 1-year price target for TMCI is 11.50USD with a low forecast of9.00USD and a high forecast of16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
4 Hold
0 Sell
Moderate Buy
up Image
46.50% Upside
Current: 7.850
sliders
Low
9.00
Averages
11.50
High
16.00
Truist Securities
Richard Newitter
Hold
Maintains
$10 → $9.5
2025-03-13
Reason
Truist lowered the firm's price target on Treace Medical to $9.50 from $10 and keeps a Hold rating on the shares after its recent non-deal roadshow with CEO John Treace. Discussions mostly centered on Lapiplasty competition and new MIS Osteotomy launches, which - along with higher Lapiplasty reimbursement - should allow revenue growth to re-accelerate back to 10% ore more in Q2-Q4, the analyst tells investors in a research note. The firm remains on hold however pending greater confidence that new rollouts can sustain double-digit growth beyond easy 2025 comps, Truist adds.
Truist Securities
Richard Newitter
Hold
Maintains
$8.4 → $10
2025-03-03
Reason
Lake Street
Ben Haynor
Strong Buy
Initiates
$15
2024-12-31
Reason
Lake Street analyst Ben Haynor initiated coverage of Treace Medical with a Buy rating and $14.50 price target. Foot and ankle orthopedics is a space "ignored by both investors and industry participants" despite being a $5B-plus global market growing at a 7%-8% compound annual growth rate, the analyst contends. The analyst, who thinks "the Street has fully digested (and overreacted to) the challenges Treace has faced," sees Treace gearing up for several major portfolio additions in the first half of 2025 and adds that key CMS reimbursement "doubles tomorrow."
Truist Securities
Richard Newitter
Hold
Maintains
$7 → $8.4
2024-12-18
Reason
Truist raised the firm's price target on Treace Medical to $8.40 from $7 and keeps a Hold rating on the shares as part of a broader research note previewing 2025 in Medical Technology. The firm sees the sector as "one of the better/safer houses" in healthcare given its lower "front-line" exposure to healthcare policy rhetoric that is tied to the administration change as well as its position as an "innovation segment" with sustainable above-average revenue and EPS growth, strong balance sheets, and healthy free cash flows. Truist adds that it prefers small-mid size companies over large caps as M&A may be "poised to heat up".
JP Morgan
Lilia-Celine Lozada
Hold
Initiates
$8
2024-12-17
Reason
JPMorgan assumed coverage of Treace Medical with a Neutral rating and $8 price target. While believers in the company's Lapiplasty value proposition, the firm thinks Treace has more work to do to restore growth and investor confidence in the long-term outlook.
Stifel
Rick Wise
Hold
Maintains
$7 → $8
2024-11-06
Reason
Truist Securities
Richard Newitter
Hold
Maintains
$7.5 → $6
2024-10-14
Reason
Truist Securities
Richard Newitter
Hold
Maintains
$9 → $7.5
2024-08-07
Reason
UBS
Danielle Antalffy
Hold
Maintains
$6.5 → $7
2024-08-07
Reason
Truist Securities
Richard Newitter
Hold
Maintains
$7 → $9
2024-07-16
Reason

Valuation Metrics

The current forward P/E ratio for Treace Medical Concepts Inc(TMCI.O) is -9.75, compared to its 5-year average forward P/E of -35.64. For a more detailed relative valuation and DCF analysis to assess Treace Medical Concepts Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-35.64
Current PE
-9.75
Overvalued PE
-0.67
Undervalued PE
-70.61

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.43
Current EV/EBITDA
2429.91
Overvalued EV/EBITDA
462.64
Undervalued EV/EBITDA
-471.50

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
6.45
Current PS
2.31
Overvalued PS
10.41
Undervalued PS
2.49

Financials

Annual
Quarterly
FY2024Q4
YoY :
+10.44%
68.71M
Total Revenue
FY2024Q4
YoY :
-96.99%
-204.00K
Operating Profit
FY2024Q4
YoY :
-92.02%
-501.00K
Net Income after Tax
FY2024Q4
YoY :
-90.00%
-0.01
EPS - Diluted
FY2024Q4
YoY :
+324.30%
-7.28M
Free Cash Flow
FY2024Q4
YoY :
-1.01%
80.74
Gross Profit Margin - %
FY2024Q4
YoY :
-5.33%
-23.29
FCF Margin - %
FY2024Q4
YoY :
-92.77%
-0.73
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
398.5K
USD
1
3-6
Months
1.0M
USD
1
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
1
524.1K
USD
Months
3-6
0
0.0
USD
Months
6-9
3
1.3M
USD
Months
0-12
16
5.9M
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
2
2.0M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

TMCI News & Events

Events Timeline
2025-02-27 (ET)
2025-02-27
16:29:45
Treace Medical reports Q4 EPS (1c), consensus (4c)
select
2025-01-30 (ET)
2025-01-30
07:15:35
Treace Medical announces completion of first cases using SpeedAkin ACI
select
2025-01-13 (ET)
2025-01-13
07:08:21
Treace Medical reports preliminary Q4 revenue $68.4M-$68.8M, consensus $67.02M
select
2024-12-30 (ET)
2024-12-30
07:17:52
Treace announces limited market release of Percuplastry system, procedure
select
2024-12-04 (ET)
2024-12-04
15:35:19
Treace announces cases using RedPoint Intelliguide PSI with Adductoplasty
select
2024-12-02 (ET)
2024-12-02
15:34:00
Treace Medical announces Guy Guglielmino as chief commercial officer
select
2024-11-05 (ET)
2024-11-05
15:24:41
Treace Medical reports Q3 EPS (25c), consensus (27c)
select
2024-10-14 (ET)
2024-10-14
09:48:23
Treace Medical sees 2024 adjusted EBITDA improving 50% vs. 2023
select
2024-10-14
09:47:57
Treace Medical files patent infringement suit against Stryker
select
2024-09-11 (ET)
2024-09-11
08:14:26
Treace Medical will highlight new production innovations at AOFAS meeting
select
News
3.5
03-25Newsfilter
Treace Highlights New Innovations at the 2025 ACFAS Annual Scientific Conference
5.0
03-20NASDAQ.COM
Insider Sale: Chief Innovation Officer of $TMCI Sells 50,000 Shares
4.0
03-13Benzinga
Truist Securities Maintains Hold on Treace Medical Concepts, Lowers Price Target to $9.5
6.0
03-13Business Insider
Truist Financial Sticks to Its Hold Rating for Treace Medical Concepts (TMCI)
5.0
03-04Business Insider
Treace Medical CEO buys $524K in common stock
5.0
03-04NASDAQ.COM
Insider Purchase: Chief Executive Officer of $TMCI Buys 60,000 Shares
6.0
02-27Business Insider
Analysts Offer Insights on Healthcare Companies: Verve Therapeutics (VERV), Treace Medical Concepts (TMCI) and Jasper Therapeutics (JSPR)
2.0
02-07Benzinga
Why Pinterest Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
2.0
02-06Newsfilter
Treace to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025
4.0
02-04Business Insider
Positive Report for Treace Medical Concepts (TMCI) from BTIG
9.0
01-21Benzinga
Why INNOVATE Shares Are Trading Higher By Over 19%; Here Are 20 Stocks Moving Premarket
2.0
01-17Benzinga
Why Versus Systems Shares Are Trading Higher By Around 71%; Here Are 20 Stocks Moving Premarket
9.5
01-13Business Insider
Treace Medical Preliminary Q4, FY24 Revenues Beat Expectations; Stock Up
7.0
01-09Businesswire
The Law Offices of Frank R. Cruz Continues Its Investigation of Treace Medical Concepts, Inc. (TMCI) on Behalf of Investors
8.5
2024-12-31Business Insider
CompoSecure to spin off Resolute, EHang raises Q4 revenue view; Morning Buzz
4.0
2024-12-31Benzinga
This Vertex Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Tuesday
4.0
2024-12-31Benzinga
Lake Street Initiates Coverage On Treace Medical Concepts with Buy Rating, Announces Price Target of $14.5
5.0
2024-12-30Newsfilter
Treace Expands Reach into High-Volume Osteotomy Market with Second MIS Osteotomy Platform, Percuplasty™ Percutaneous 3D Bunion Correction® Procedure
4.0
2024-12-18Benzinga
Deep Dive Into Treace Medical Concepts Stock: Analyst Perspectives (4 Ratings)
5.0
2024-12-16Newsfilter
Treace Announces First Surgical Cases Utilizing the SpeedPlate™ MicroQuad™ Implant

FAQ

arrow icon

What is Treace Medical Concepts Inc (TMCI) stock price today?

The current price of TMCI is 7.85 USD — it hasdecreased-5.65 % in the last trading day.

arrow icon

What is Treace Medical Concepts Inc (TMCI)'s business?

arrow icon

What is the price predicton of TMCI Stock?

arrow icon

What is Treace Medical Concepts Inc (TMCI)'s revenue for the last quarter?

arrow icon

What is Treace Medical Concepts Inc (TMCI)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Treace Medical Concepts Inc (TMCI)'s fundamentals?

arrow icon

How many employees does Treace Medical Concepts Inc (TMCI). have?

arrow icon

What is Treace Medical Concepts Inc (TMCI) market cap?